Beam Therapeutics Inc.

Listed Company

BEAMCIK 0001745999NasdaqLarge AcceleratedBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

$139.74M

Net Income

$-79.99M

Total Assets

$1.48B

Equity

$1.24B

Shares Out

102.88M

Op. Cash Flow

$-345.10M

BEAM$27.54+34.65% · past yearDBEQ Basic

Daily closing prices

Business

Beam Therapeutics is a biotechnology company developing precision genetic medicines using proprietary base editing technology that modifies single DNA bases without double-stranded breaks. The company offers a platform combining base editors, delivery modalities (ex vivo and in vivo), and internal manufacturing capabilities. Lead programs include risto-cel for sickle cell disease, BEAM-302 for alpha-1 antitrypsin deficiency, and programs for phenylketonuria and glycogen storage disease, with development in hematology and genetic disease portfolios. The company operates in clinical development stages with programs in the United States and partnerships with major pharmaceutical companies.

Summary from 10-K filed 2026-02-24

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
License and collaboration revenue	140	64	378	61	52
Research and development	410	368	437	312	387
General and administrative	114	112	117	88	57
Total operating expenses	523	479	554	399	444
Loss from operations	−384	−416	−176	−338	−392
Change in fair value of derivative liabilities	700,000	2	8	24	−1
Change in fair value of non-controlling equity investments	4	−14	−19	20	18
Change in fair value of contingent consideration liabilities	180,000	2	10	—	—
Gain on sale of equity method investment	255	—	—	−26	—
Interest and other income (expense), net	44	49	47	15	−9,000
Total other income (expense)	304	39	45	78	22
Net loss before income taxes	−80	−377	−131	−260	−371
Provision for income taxes	0	−39,000	−1	−3	0
Net loss	−80	−377	−133	−289	−371
Unrealized gain (loss) on marketable securities	432,000	75,000	3	−2	−41,000
Comprehensive loss	−80	−377	−129	−291	−371
Net loss per common share, basic	−0.81	−4.58	−1.72	−4.13	−5.77
Net loss per common share, diluted	−0.81	−4.58	−1.72	−4.13	−5.77
Weighted - average common shares outstanding, basic	99	82	77	70	64
Weighted - average common shares outstanding, diluted	99	82	77	70	64

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	295	282	436	233	560
Marketable securities	950	569	—	—	—
Prepaid expenses and other current assets	23	27	21	15	7
Total current assets	1,269	878	1,211	1,093	1,273
Property and equipment, net	105	111	125	116	84
Restricted cash	7	8	9	13	13
Operating lease right-of-use assets	101	105	113	119	103
Other assets	634,000	1	2	2	2
Total assets	1,481	1,104	1,460	1,342	1,474
Accounts payable	10	4	2	9	7
Accrued expenses and other current liabilities	55	47	—	—	—
Current portion of derivative liabilities	8	8	11	18	42
Current portion of deferred revenue	7	109	69	136	86
Current portion of lease liability	14	13	13	10	8
Current portion of contingent consideration liabilities	3	—	—	—	—
Total current liabilities	97	182	206	224	213
Long-term lease liability	140	148	160	169	135
Long-term portion of contingent consideration liabilities	6	1	3	12	31
Long-term portion of deferred revenue	0	33	110	202	262
Long-term portion of derivative liabilities	0	5	—	—	—
Other liabilities	173,000	504,000	298,000	1	3
Total liabilities	243	370	478	608	648
Commitments and contingencies (See Note 9, License and other agreements and Note 10, Collaboration and license agreements)	—	—	—	—	—
Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at December 31, 2025 and December 31, 2024 respectively	—	—	—	—	—
Common stock, $0.01 par value; 250,000,000 shares authorized, 101,748,962 and 83,633,069 issued and outstanding at December 31, 2025 and December 31, 2024, respectively	1	836,000	816,000	712,000	684,000
Additional paid-in capital	2,877	2,299	2,170	1,793	1,594
Accumulated other comprehensive (loss) income	1	679,000	604,000	−2	−50,000
Accumulated deficit	−1,600	−1,567	−1,190	−1,057	−768
Total stockholders' equity	1,238	734	981	733	827
Total liabilities and stockholders' equity	1,481	1,104	1,460	1,342	1,474

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−80	−377	−133	−289	−371
Depreciation and amortization	22	22	20	14	7
Amortization of investment discount (premiums)	−16	−23	−30	−9	−75,000
In-process research and development charge	15	0	0	—	155
Stock-based compensation expense	94	121	99	84	44
Change in operating lease right-of-use assets	10	10	10	8	9
Realized loss (gain) on sale of marketable securities	399,000	0	0	—	—
Gain on sale of equity method investment	−255	0	0	—	—
Prepaid expenses and other current assets	5	−5	−7	−8	746,000
Accounts payable	6	2	−8	2	818,000
Accrued expenses and other liabilities	8	−58	68	−17	44
Operating lease liabilities	−14	−13	−10	12	16
Deferred revenue	−135	−37	−160	−36	348
Other long-term liabilities	−330,000	473,000	−194,000	−3	2
Net cash provided by (used in) operating activities	−345	−347	−149	23	−66
Purchases of property and equipment	−15	−9	−34	−49	−47
Purchases of marketable securities	−1,210	−486	−984	−1,617	−777
Maturities of marketable securities	842	680	1,090	1,205	529
Proceeds from sale of marketable securities	6	0	0	—	—
Cash paid for acquisition, net	−78,000	0	0	—	—
Proceeds from sale of equity method investment	255	0	0	—	—
Net cash provided by (used in) investing activities	−121	185	72	−461	−294
Proceeds from issuance of common shares and pre-funded warrants, net of issuance costs	471	0	236	—	—
Proceeds from issuances of stock under ESPP	3	3	3	3	—
Equipment financings, net	0	−485,000	−2	−2	−2
Proceeds from exercise of stock options	5	6	6	3	10
Proceeds from private stock issuance	0	0	34	—	—
Net cash provided by (used in) financing activities	478	8	276	112	756
Net change in cash, cash equivalents and restricted cash	12	−155	199	−327	396
Cash paid for interest	0	32,000	160,000	376,000	567,000
Property and equipment additions in accounts payable and accrued expenses	1	834,000	1	6	9
Operating lease liabilities arising from obtaining right-of-use assets	6	−2	4	41	—
Contingent consideration liabilities assumed in acquisition	8	0	0	—	37
Fair value of equity instruments issued in connection with acquisition	7	0	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Beam Therapeutics Inc.'s CIK number?

Beam Therapeutics Inc.'s SEC CIK number is 0001745999 (1745999). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Beam Therapeutics Inc.'s SEC filings?

All of Beam Therapeutics Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Beam Therapeutics Inc. last report earnings?

Beam Therapeutics Inc. (BEAM) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-210299). This is Beam Therapeutics Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Beam Therapeutics Inc.'s most recent earnings 8-K?

Beam Therapeutics Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001193125-26-210299. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Beam Therapeutics Inc.'s latest earnings 8-K →
Look up any company's CIK number →